QIAGEN has announced a new partnership with GENCURIX, marking the launch of the QIAcuityDx Partnering Program. This collaboration focuses on developing oncology assays for the QIAcuityDx platform, a digital PCR system intended for clinical diagnostics. As the inaugural partner, GENCURIX will develop multiplex oncology assays targeting both tissue and liquid biopsies. The partnership aims to broaden the adoption of the QIAcuityDx Four platform, offering clinical diagnostic laboratories a wide range of oncology assays. This strategic alliance is expected to expand GENCURIX's diagnostic technologies into the global market, leveraging QIAGEN's platform for precision cancer diagnostics.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.